ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO067

Prevalence of G1 and G2 APOL1 Gene Variants in Afrodescendant Patients from the Unit of Kidney Transplant in a High Complexity Medical Center in Cali, Colombia

Session Information

Category: Genetic Diseases of the Kidney

  • 1002 Genetic Diseases of the Kidney: Non-Cystic

Author

  • Rebolledo, Carlos Durán, Fundacion Valle del Lili, Cali, Valle, Colombia
Background

In recent years, the presence of APOL1 genetic variants has been recognized as a risk factor of chronic kidney disease in afrodescendant patients, especially variants related to the risk alleles G1 and G2 (1)(2). Patients with two allelic variants are at higher risk, and tend to require dialysis up to 9 years earlier than patients with no risk alleles (2). In addition, receptors of kidney transplant from donors with APOL1 variants seem to have a worse posttransplant prognosis and higher risk of graft dysfunction (3)(4)(5).
The aim of this study is to determine the prevalence of these allelic variants among the afrodescendant patients from the kidney transplant unit at Fundacion Valle del Lili (FVL).

Methods

Observational, cross-sectional study including afrodescendant patients with chronic kidney disease from the kidney transplant unit at FVL, who were on the waitlist or were already recipients of kidney transplant. The study period was defined from January to November 2017

Results

A total of 103 patients were included, 56% (n=57) were female. The mean age was 48 years old (SD 13 years), the mean time of dialysis before kidney transplant was 4 years, 89% had clinical history of arterial hypertension.
APOL1 gene variants were found in 62% (n=64) of patients, of them 32.8% (n=21) were G1 heterozygotes, 39% (n=25) were G1 homozygotes, 4.6% (n=3) were G2 homozygotes, and 23.4% (n=15) were mixed G1/G2. There were none G2 heterozygotes.

Conclusion

This study describes that in the afrodescendant population with chronic kidney disease at FVL the frequency of APOL1 variants is high, nevertheless these results cannot be extrapolated to the general population, and larger population studies are required to accurately assess the frequency of APOL1 variants in our country. This study represents a cornerstone for new lines of research on this field in our institution, a national referral center for kidney transplants.